171805-85-9Relevant academic research and scientific papers
New short synthesis of (5)-2,3-dimethoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl] -5-iodobenzamide: Dopamine D2 receptor
Joshua, Alummoottil V.,Sharma, Sanjay K.,Abrams, Douglas N.
, p. 434 - 440 (2008)
A new short and highly efficient synthesis of (5)-2,3-dimethoxy-N[(1-ethyl- 2-pyrrolidinyl)methyl]-5-iodobenzamide (epidepride, 1) from 3-methoxy- salicylaldehyde (o-vanillin, 2) and 3-methoxysalicyclic acid (6) was achieved by employing a new iodination
Synthesis and 5-HT-3 receptor binding activity of 5-[125I]iodo-2,3-dimethoxy-N-(1-azabicyclo[2.2.2]oct-3-yl]benzamide and its 5-halogen-2-alkoxyl homologues
De Paulis,Hewlett,Schmidt,Mason,Trivedi,Ebert
, p. 385 - 396 (2007/10/03)
(S)-5-Iodo-2,3-dimethoxy-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamide (MIZAC) was prepared from 5-iodo-2,3-dimethoxybenzoyl chloride and (S)-3-aminoquinuclidine. [125I]Iodode-stannylation of its corresponding 5-tri-n-butyltin derivative gave [125I]-MIZAC at 1800 Ci/mmol. Binding of [125I]-MIZAC in rat entorhinal cortex revealed a K(D) of 1.37 ± 0.21 nM. A series of racemic 2-O-alkyl derivatives of MIZAC were prepared and 5-HT-3 receptor affinities were determined by inhibition of [125I]-MIZAC binding. Optimal affinity for the receptor was obtained with small, electron-withdrawing substituents in the aromatic 5-position and with bulky substituents in the 3-position. [125I]-MIZAC is a selective radioligand useful for in vitro identification of the 5-HT-3 receptor.
Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT
Chumpradit,Kung,Billings,Mach,Kung
, p. 221 - 228 (2007/10/02)
A novel series of dual-labeling D2 dopamine agents (labeled with either 18F or 123I for PET or SPECT imaging, respectively) was investigated. Two desired fluorinated and iodinated dopamine agents, FIDA1, (S)-(-)-2-(2- fluoroethoxy)-5
